BCRX
BioCryst Pharmaceuticals Inc
8.70$
-0.2%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.9% | 3.9% | 10.2% | 6.8% | 2.3% | 8.4% | 9.4% | 4.6% | 2.4% | 1.4% | 2.8% | 2.2% | |
| 99.1% | 96.1% | 89.8% | 93.2% | 97.7% | 91.6% | 90.6% | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% | |
| 380.6% | 150.8% | 231.5% | 265.9% | 411.0% | 219.2% | 690.3% | 132.9% | 93.5% | 65.3% | 38.7% | 19.0% | |
| 54.8% | 27.0% | 42.7% | 55.3% | 142.9% | 76.0% | 344.5% | 72.0% | 53.3% | 60.1% | 56.0% | 39.9% | |
| 435.5% | 177.8% | 274.2% | 321.2% | 553.9% | 295.3% | 1,071.7% | 208.5% | 152.4% | 129.9% | 97.8% | 58.8% | |
| -336.4% | -81.7% | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% | |
| 36.7% | 10.8% | 24.6% | 34.0% | 44.4% | 24.4% | 81.4% | 37.7% | 36.6% | 32.7% | 21.9% | 9.0% | |
| -332.1% | -89.1% | -209.3% | -261.2% | -490.3% | -223.0% | -1,026.4% | -115.7% | -90.2% | -68.3% | -19.3% | 30.6% | |
| 35.4% | 10.4% | 22.8% | 31.2% | 10.4% | 22.9% | 77.2% | 1.4% | 1.0% | 0.1% | 0.4% | 0.4% | |
| -332.1% | -89.1% | -209.3% | -261.2% | -490.3% | -223.0% | -1,026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% | |
| -294.0% | -78.0% | -182.8% | -224.4% | -437.5% | -197.2% | -940.7% | -77.5% | -53.1% | -35.1% | 2.8% | 39.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.